Skip to main content

Table 6 Laboratory abnormalities in all-treated patients with baseline normal values a

From: A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

 

Telavancin

Standard therapy

 

n/N

n/N

Hematocrit

  

  Male, ≤30%

1/4 (25%)

0/1 (0%)

  Female, ≤28%

0/4 (0%)

0/3 (0%)

WBC ≤2800/μl

0/14 (0%)

0/15 (0%)

Platelet count ≤75,000/μl

0/18 (0%)

0/13 (0%)

AST (≥3 ULN)

3/18 (17%)

0/18 (0%)

ALT (≥3 ULN)

1/19 (5%)

1/17 (6%)

Alkaline phosphatase (≥1.5 ULN)

2/17 (12%)

1/22 (5%)

Potassium <3 meq/l

2/24 (8%)

0/19 (0%)

Potassium >5.5 meq/l

1/24 (4%)

3/19 (16%)

Creatinine increaseb

5/25 (20%)

2/28 (7%)

  Baseline creatinine <1.5 mg/dl

4/18 (22%)

0/20 (0%)

  Baseline creatinine ≥1.5 mg/dl

1/7 (14%)

2/8 (25%)

  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase, ULN, upper limit of normal; WBC, white blood count.
  2. aIncludes laboratory assessments after initiation of study drug up to and including the earlier of the follow-up visit or 28 days after the last dose of study medication.
  3. bSerum creatinine ≥1.5 mg/dl and at least 50% greater than baseline; includes patients with normal and abnormal values at baseline.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us